Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary

Lajos Hornyák, Zsolt Nagy, Lívia Ilku, Zsuzsanna Tálos, Dóra Endrei, István Ágoston, Tímea Csákvári, Nóra Danku, Balázs Répásy, Imre Boncz

Research output: Contribution to journalArticle

Abstract

Objectives: We analyzed the bid approach of the Hungarian National Health Insurance Fund Administration (NHIFA) based on the results of two consecutive bids on colony stimulating factor (CSF). Methods: The Hungarian NHIFA database was used to analyze the changes in the number of patients treated with CSF and reimbursement paid by NHIFA, 12 months preceding and following the bids. Results: 13,974 patients received granulocyte-CSF treatment during 12 months prior to bidding. A 4.5% decrease (13,352) and further 1.3% decrease (13,185) in the total number of patients were observed during the first and second years, respectively. The annual health insurance subsidy paid during 12 months prior to the bids was. 7.49 billion Hungarian Forint (HUF) or 26.8 million Euro (EUR). In the first year following the bid, we found a 3.3 billion HUF (12.4 million EUR) decrease in health insurance subsidy (44% reduction). A further 7.9% reduction was observed during the second year, resulting in an annual health insurance subsidy of 3.59 billion HUF (12.1 million EUR). Conclusion: During the 2 years bid (public procurement procedure), the National Health Insurance Fund Administration managed to reduce the health insurance subsidy paid for the reimbursement of both original and biosimilar G-CSF products.

Original languageEnglish
Pages (from-to)725-731
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume19
Issue number6
DOIs
Publication statusPublished - Nov 2 2019

    Fingerprint

Keywords

  • Biosimilars
  • colony stimulating factor
  • competition in price
  • drug market

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this